NeuroMetrix, Inc. Announces Date for 2013 Second Quarter Financial Results Conference Call Business Wire WALTHAM, Mass. -- July 17, 2013 NeuroMetrix, Inc. (Nasdaq: NURO), today said it plans to issue its 2013 second quarter financial results before the opening of the market on July 25, 2013. The Company will host a conference call at 8:00 a.m., Eastern Time on July 25, 2013 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 866-510-0707 and using the confirmation code 18430936. Internationally, the conference call may be accessed by dialing 617-597-5376 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.neurometrix.com under the "Investors" tab. A replay of the conference call will be available starting two hours after the call by dialing 888-286-8010, domestically and 617-801-6888, internationally. The confirmation code to access the replay is 19088827. The replay will be available for two weeks after the conference call. About NeuroMetrix NeuroMetrixis a medical device company that develops and markets home use and point-of-care devices for the treatment and management of diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at$14 billionintheUnited States. The company’s products are used by physicians and managed care organizations to optimize patient care and reduce healthcare costs. The company markets the SENSUS^™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy and similar peripheral neuropathies. The company also markets the NC-stat^®DPNCheck^®device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visithttp://www.neurometrix.com. Contact: NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief Financial Officer firstname.lastname@example.org
NeuroMetrix, Inc. Announces Date for 2013 Second Quarter Financial Results Conference Call
Press spacebar to pause and continue. Press esc to stop.